Merck & Co. Inc.'s announcement that its PD-1 inhibitor Keytruda combined with chemotherapy demonstrated overall survival and progression-free survival benefits in the KEYNOTE-407 study in first-line squamous non-small lung cancer (NSCLC) support the drug's role in this indication and dominance in the tumor type generally.
Merck announced May 23 that the combination of Keytruda (pembrolizumab) and chemo demonstrated benefits for the co-primary endpoints of progression-free survival (PFS) and overall survival (OS) versus chemotherapy alone in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?